Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.

Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.

Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...